Company profile
Vertex Pharmaceuticals Incorporated
NASDAQ: VRTX · Healthcare · Biotechnology
#38 of 1,422 Healthcare companies by revenue55th-percentile growth
EA Score
88AFH 90DQ 93GM 68SS 96
v0.1 · 65/100 weight · provisional
↑ market scale, operating margin · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$12.3B
Rev growth YoY (TTM)
+10.4%
Net income (FY)
$4.0B
Employees
6,400
as of 2026-08-04
Market cap
$119.5B
as of 2026-08-04
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$12.0B$12.0B2025
Net income$4.0B$4.0B2025
Operating income$4.2B$4.2B2025
Total assets$25.6B$25.6B2025
Liabilities$7.0B$7.0B2025
Equity$18.7B$18.7B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
TRIKAFTA/KAFTRIO86%
ALYFTREK7%
Manufactured Product, Other7%
By geography
UNITED STATES46%
Non-US33%
Europe21%
The read
What is Vertex Pharmaceuticals Incorporated’s revenue?
Vertex Pharmaceuticals Incorporated booked $12.0B in FY2025 revenue, growing 8.9% year over year — about the middle of the pack among Healthcare companies we track, at a 32.9% net margin.
Peers · Healthcare
Henry Schein, Inc.77B+BrightSpring Health Services, Inc. Common Stock69BCommunity Health Systems, Inc.74BBaxter International Inc.78B+Quest Diagnostics Incorporated88ABausch Health Companies Inc.82B+Neighbors
Suffolk →Key facts
CEOReshma Kewalramani
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: VRTX
Employees6,400
IPO date1991-07-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.